MX2014005289A - Compuestos de piperazina alquilados. - Google Patents
Compuestos de piperazina alquilados.Info
- Publication number
- MX2014005289A MX2014005289A MX2014005289A MX2014005289A MX2014005289A MX 2014005289 A MX2014005289 A MX 2014005289A MX 2014005289 A MX2014005289 A MX 2014005289A MX 2014005289 A MX2014005289 A MX 2014005289A MX 2014005289 A MX2014005289 A MX 2014005289A
- Authority
- MX
- Mexico
- Prior art keywords
- inhibitors
- piperazine compounds
- btk activity
- alkylated piperazine
- compounds
- Prior art date
Links
- 150000004885 piperazines Chemical class 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 102000001253 Protein Kinase Human genes 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 208000026278 immune system disease Diseases 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 238000011065 in-situ storage Methods 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 210000004962 mammalian cell Anatomy 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
- 108060006633 protein kinase Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Obesity (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Vascular Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161555395P | 2011-11-03 | 2011-11-03 | |
| PCT/US2012/063198 WO2013067277A1 (en) | 2011-11-03 | 2012-11-02 | Alkylated piperazine compounds as inhibitors of btk activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2014005289A true MX2014005289A (es) | 2014-05-30 |
Family
ID=47146780
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014005289A MX2014005289A (es) | 2011-11-03 | 2012-11-02 | Compuestos de piperazina alquilados. |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US8729072B2 (enExample) |
| EP (1) | EP2773639B1 (enExample) |
| JP (2) | JP5976828B2 (enExample) |
| KR (1) | KR101716011B1 (enExample) |
| CN (1) | CN104024255B (enExample) |
| AR (1) | AR088642A1 (enExample) |
| AU (1) | AU2012332368A1 (enExample) |
| BR (1) | BR112014010439A2 (enExample) |
| CA (1) | CA2853970A1 (enExample) |
| CL (1) | CL2014001158A1 (enExample) |
| CO (1) | CO6950475A2 (enExample) |
| CR (1) | CR20140187A (enExample) |
| EA (1) | EA027561B1 (enExample) |
| IL (1) | IL232280A0 (enExample) |
| IN (1) | IN2014CN03265A (enExample) |
| MA (1) | MA35725B1 (enExample) |
| MX (1) | MX2014005289A (enExample) |
| PE (1) | PE20141686A1 (enExample) |
| PH (1) | PH12014500966A1 (enExample) |
| SG (1) | SG11201401993RA (enExample) |
| TW (1) | TW201326171A (enExample) |
| WO (1) | WO2013067277A1 (enExample) |
| ZA (1) | ZA201403158B (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013021374A2 (en) | 2011-08-05 | 2013-02-14 | Mitraltech Ltd. | Techniques for percutaneous mitral valve replacement and sealing |
| BR112014010439A2 (pt) * | 2011-11-03 | 2017-04-18 | F Hoffmann - La Roche Ag | compostos, composição farmacêutica, processo de produção, método de tratamento de uma doença ou distúrbio, métodos, kit e uso de uma composição farmacêutica |
| UA111756C2 (uk) * | 2011-11-03 | 2016-06-10 | Ф. Хоффманн-Ля Рош Аг | Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона |
| WO2015000949A1 (en) | 2013-07-03 | 2015-01-08 | F. Hoffmann-La Roche Ag | Heteroaryl pyridone and aza-pyridone amide compounds |
| EP3077384B1 (en) | 2013-12-05 | 2017-09-06 | F. Hoffmann-La Roche AG | Heteroaryl pyridone and aza-pyridone compounds with electrophilic functionality |
| JP6879740B2 (ja) | 2013-12-13 | 2021-06-02 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | リンパ形質細胞性リンパ腫を処置する方法 |
| US9908872B2 (en) | 2013-12-13 | 2018-03-06 | Dana-Farber Cancer Institute, Inc. | Methods to treat lymphoplasmacytic lymphoma |
| WO2015151006A1 (en) | 2014-03-29 | 2015-10-08 | Lupin Limited | Substituted purine compounds as btk inhibitors |
| CA2946538A1 (en) | 2014-04-04 | 2015-10-08 | Del Mar Pharmaceuticals | Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer |
| WO2015170266A1 (en) | 2014-05-07 | 2015-11-12 | Lupin Limited | Substituted pyrimidine compounds as btk inhibitors |
| CN106922146B (zh) | 2014-10-02 | 2020-05-26 | 豪夫迈·罗氏有限公司 | 用于治疗由布鲁顿酪氨酸激酶(btk)介导的疾病的吡唑甲酰胺化合物 |
| JP6788583B2 (ja) | 2014-10-22 | 2020-11-25 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | 増殖性疾患を処置するためのチアゾリル含有化合物 |
| WO2016066490A1 (en) | 2014-10-27 | 2016-05-06 | F. Hoffmann-La Roche Ag | Process for making tricyclic lactam compounds |
| CN105837576B (zh) | 2015-01-14 | 2019-03-26 | 湖北生物医药产业技术研究院有限公司 | Btk抑制剂 |
| MX384444B (es) * | 2015-03-10 | 2025-03-14 | Aurigene Discovery Tech Ltd | Compuestos de 1,2,4-oxadiazol y tiadiazol como inmunomoduladores |
| BR112018069530B1 (pt) | 2016-02-29 | 2021-02-17 | F. Hoffmann-La Roche Ag | composições de forma de dosagem que compreendem um inibidor da tirosina quinase de bruton |
| EP3548046A2 (en) | 2016-12-03 | 2019-10-09 | Juno Therapeutics, Inc. | Methods and compositions for use of therapeutic t cells in combination with kinase inhibitors |
| AU2017376580B2 (en) * | 2016-12-15 | 2020-08-13 | F. Hoffmann-La Roche Ag | Process for preparing BTK inhibitors |
| CN107445981B (zh) * | 2017-08-25 | 2018-06-22 | 牡丹江医学院 | 一种用于防治宫颈炎的活性化合物 |
| EP3930717A1 (en) | 2019-02-25 | 2022-01-05 | Guangzhou Lupeng Pharmaceutical Company Ltd. | Inhibitor of btk and mutants thereof |
| BR112021018168B1 (pt) | 2019-03-21 | 2023-11-28 | Onxeo | Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer |
| WO2021066958A1 (en) | 2019-10-05 | 2021-04-08 | Newave Pharmaceutical Inc. | Inhibitor of btk and mutants thereof |
| CA3159348A1 (en) | 2019-11-08 | 2021-05-14 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| WO2021164735A1 (en) | 2020-02-20 | 2021-08-26 | Hutchison Medipharma Limited | Heteroaryl heterocyclic compounds and uses thereof |
| CA3175788A1 (en) * | 2020-04-22 | 2021-10-28 | Claire LANGRISH | Treatment of acute respiratory distress syndrome and other disorders involving cytokine storm using btk inhibitors |
| US20230348471A1 (en) * | 2020-06-18 | 2023-11-02 | Shanghai Synergy Pharmaceutical Sciences Co., Ltd. | Bruton's tyrosine kinase inhibitor and preparation method therefor |
| EP4214206A4 (en) | 2020-09-21 | 2024-10-09 | Hutchison Medipharma Limited | HETEROCYCLIC HETEROARYL COMPOUNDS AND USES THEREOF |
| WO2022094172A2 (en) | 2020-10-30 | 2022-05-05 | Newave Pharmaceutical Inc. | Inhibitors of btk |
| US20240058457A1 (en) | 2020-12-20 | 2024-02-22 | Newave Pharmaceutical Inc. | Btk degrader |
| US20250154155A1 (en) * | 2022-01-28 | 2025-05-15 | Hutchmed Limited | Synthetic method of 7,8-dihydro-2h-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1(6h)-one compounds |
| CN119080748A (zh) * | 2024-08-29 | 2024-12-06 | 中南大学 | 一种靶向brd7抑瘤蛋白的增稳剂及其在制备治疗实体肿瘤药物中的应用 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US5583024A (en) | 1985-12-02 | 1996-12-10 | The Regents Of The University Of California | Recombinant expression of Coleoptera luciferase |
| US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
| JPH08336393A (ja) | 1995-04-13 | 1996-12-24 | Mitsubishi Chem Corp | 光学活性なγ−置換−β−ヒドロキシ酪酸エステルの製造法 |
| US6602677B1 (en) | 1997-09-19 | 2003-08-05 | Promega Corporation | Thermostable luciferases and methods of production |
| CN100528329C (zh) | 2001-07-12 | 2009-08-19 | 里艾克沙有限公司 | 微囊包封的催化剂,它们的制备方法和使用方法 |
| US7405295B2 (en) | 2003-06-04 | 2008-07-29 | Cgi Pharmaceuticals, Inc. | Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds |
| WO2005005429A1 (en) | 2003-06-30 | 2005-01-20 | Cellular Genomics, Inc. | Certain heterocyclic substituted imidazo[1,2-a]pyrazin-8-ylamines and methods of inhibition of bruton’s tyrosine kinase by such compounds |
| EP1812442A2 (en) | 2004-11-10 | 2007-08-01 | CGI Pharmaceuticals, Inc. | Imidazo[1,2-a]pyrazin-8-ylamines useful as modulators of kinase activity |
| MX2007011041A (es) | 2005-03-10 | 2008-02-22 | Cgi Pharmaceuticals Inc | Ciertas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas. |
| DE602006021205D1 (de) | 2005-10-07 | 2011-05-19 | Exelixis Inc | Azetidine als mek-inhibitoren bei der behandlung proliferativer erkrankungen |
| AR063706A1 (es) | 2006-09-11 | 2009-02-11 | Cgi Pharmaceuticals Inc | Determinadas amidas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden. |
| AR063946A1 (es) | 2006-09-11 | 2009-03-04 | Cgi Pharmaceuticals Inc | Determinadas pirimidinas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden. |
| US7838523B2 (en) | 2006-09-11 | 2010-11-23 | Cgi Pharmaceuticals, Inc. | Certain substituted amides, method of making, and method of use thereof |
| CL2008002793A1 (es) | 2007-09-20 | 2009-09-04 | Cgi Pharmaceuticals Inc | Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras |
| US8426441B2 (en) | 2007-12-14 | 2013-04-23 | Roche Palo Alto Llc | Inhibitors of bruton's tyrosine kinase |
| US7683064B2 (en) | 2008-02-05 | 2010-03-23 | Roche Palo Alto Llc | Inhibitors of Bruton's tyrosine kinase |
| US8426424B2 (en) | 2008-05-06 | 2013-04-23 | Cgi Pharmaceuticals, Inc. | Certain substituted amides, method of making, and method of use thereof |
| WO2009156284A1 (en) | 2008-06-24 | 2009-12-30 | F. Hoffmann-La Roche Ag | Novel substituted pyridin-2-ones and pyridazin-3-ones |
| AU2009265813B2 (en) * | 2008-07-02 | 2014-04-10 | F. Hoffmann-La Roche Ag | Novel phenylpyrazinones as kinase inhibitors |
| EP2307413B1 (en) | 2008-07-15 | 2015-09-09 | F. Hoffmann-La Roche AG | Novel phenyl-imidazopyridines and pyridazines |
| US8598174B2 (en) | 2008-11-12 | 2013-12-03 | Genetech, Inc. | Pyridazinones, method of making, and method of use thereof |
| US8299077B2 (en) * | 2009-03-02 | 2012-10-30 | Roche Palo Alto Llc | Inhibitors of Bruton's tyrosine kinase |
| CA2748414A1 (en) * | 2009-04-24 | 2010-10-28 | F. Hoffmann-La Roche Ag | Inhibitors of bruton's tyrosine kinase |
| JP5656976B2 (ja) * | 2009-04-29 | 2015-01-21 | ローカス ファーマシューティカルズ インコーポレイテッド | ピロロトリアジン化合物 |
| CA2771822C (en) * | 2009-09-04 | 2020-08-11 | Daniel A. Erlanson | Bruton's tyrosine kinase inhibitors |
| CN110818724B (zh) * | 2010-05-07 | 2020-11-13 | 吉利德康涅狄格有限公司 | 吡啶酮和氮杂吡啶酮化合物及使用方法 |
| AR082590A1 (es) | 2010-08-12 | 2012-12-19 | Hoffmann La Roche | Inhibidores de la tirosina-quinasa de bruton |
| US9249123B2 (en) | 2010-09-01 | 2016-02-02 | Genentech, Inc. | Pyridinones/pyrazinones, method of making, and method of use thereof |
| JP5842004B2 (ja) | 2010-09-01 | 2016-01-13 | ジーアイリード コネチカット インコーポレーテッドＧｉｌｅａｄ Ｃｏｎｎｅｃｔｉｃｕｔ，Ｉｎｃ． | ピリダジノン、その製造方法及びその使用方法 |
| CA2834077A1 (en) | 2011-05-17 | 2012-11-22 | F. Hoffmann-La Roche Ag | Inhibitors of bruton's tyrosine kinase |
| BR112014003582A2 (pt) | 2011-08-17 | 2017-03-14 | Hoffmann La Roche | inibidores da tirosina quinase de bruton |
| UA111756C2 (uk) * | 2011-11-03 | 2016-06-10 | Ф. Хоффманн-Ля Рош Аг | Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона |
| BR112014010439A2 (pt) * | 2011-11-03 | 2017-04-18 | F Hoffmann - La Roche Ag | compostos, composição farmacêutica, processo de produção, método de tratamento de uma doença ou distúrbio, métodos, kit e uso de uma composição farmacêutica |
-
2012
- 2012-11-02 BR BR112014010439A patent/BR112014010439A2/pt not_active Application Discontinuation
- 2012-11-02 US US13/667,114 patent/US8729072B2/en active Active
- 2012-11-02 PH PH1/2014/500966A patent/PH12014500966A1/en unknown
- 2012-11-02 AR ARP120104129A patent/AR088642A1/es unknown
- 2012-11-02 EP EP12783838.1A patent/EP2773639B1/en not_active Not-in-force
- 2012-11-02 CA CA2853970A patent/CA2853970A1/en not_active Abandoned
- 2012-11-02 WO PCT/US2012/063198 patent/WO2013067277A1/en not_active Ceased
- 2012-11-02 TW TW101140859A patent/TW201326171A/zh unknown
- 2012-11-02 CN CN201280065838.8A patent/CN104024255B/zh not_active Expired - Fee Related
- 2012-11-02 AU AU2012332368A patent/AU2012332368A1/en not_active Abandoned
- 2012-11-02 IN IN3265CHN2014 patent/IN2014CN03265A/en unknown
- 2012-11-02 KR KR1020147014782A patent/KR101716011B1/ko not_active Expired - Fee Related
- 2012-11-02 MX MX2014005289A patent/MX2014005289A/es active IP Right Grant
- 2012-11-02 PE PE2014000639A patent/PE20141686A1/es not_active Application Discontinuation
- 2012-11-02 JP JP2014541115A patent/JP5976828B2/ja not_active Expired - Fee Related
- 2012-11-02 SG SG11201401993RA patent/SG11201401993RA/en unknown
- 2012-11-02 EA EA201490859A patent/EA027561B1/ru not_active IP Right Cessation
-
2014
- 2014-04-07 US US14/246,471 patent/US8946213B2/en active Active
- 2014-04-24 CR CR20140187A patent/CR20140187A/es unknown
- 2014-04-28 IL IL232280A patent/IL232280A0/en unknown
- 2014-04-30 CO CO14093206A patent/CO6950475A2/es active IP Right Grant
- 2014-04-30 ZA ZA2014/03158A patent/ZA201403158B/en unknown
- 2014-05-02 CL CL2014001158A patent/CL2014001158A1/es unknown
- 2014-06-06 MA MA37107A patent/MA35725B1/fr unknown
- 2014-12-11 US US14/566,920 patent/US9115152B2/en active Active
-
2015
- 2015-08-24 JP JP2015165095A patent/JP2016028045A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12014500966A1 (en) | Alkylated piperazine compounds as inhibitors of btk activity | |
| MX2014005285A (es) | Compuestos biciclicos de piperazina. | |
| MX2014005282A (es) | Compuestos de 8-fluoroftalazin-1 (2h) -ona. | |
| PH12014500936A1 (en) | Heteroaryl pyridone and aza-pyridone compounds as inhibitors of btk activity | |
| MY160349A (en) | Pyridone and aza-pyridone compounds and methods of use | |
| MX2014014828A (es) | Compuestos de 5-azaindazol y metodos de uso. | |
| PH12015500488A1 (en) | Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use | |
| MX2016007171A (es) | Compuestos de heteroaril piridona y azapiridona con funcionalidad electrofila. | |
| MX2014001239A (es) | Compuestos de pirazolo [3,4-c] piridina y metodos de uso. | |
| MX2015018038A (es) | Compuestos de heteroaril-piridona y aza-piridona-amida. | |
| MX340013B (es) | Compuestos de benzoxazepina selectivos para fosfatidilinositol 3-cinasa (pi3k) p110 delta y metodos de uso. | |
| BR112013020329A2 (pt) | compostos heterocíclicos como inibidores da pi3-quinase | |
| PH12012501864A1 (en) | Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use | |
| SG178899A1 (en) | Raf inhibitor compounds and methods of use thereof | |
| PH12013501779B1 (en) | Pyrrolopyridines as kinase inhibitors | |
| EA201390879A1 (ru) | Трициклические ингибиторы pi3k и способы их применения | |
| SG178900A1 (en) | Raf inhibitor compounds and methods of use thereof | |
| PH12014501947A1 (en) | Serine/threonine kinase inhibitors | |
| MX2016012007A (es) | Compuestos de oxepan-2-il-pirazol-4-il-heterociclil-carboxamida y metodos de uso. | |
| NZ620928A (en) | Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use | |
| MA42864B1 (fr) | Composes d’éther cyclique-pyrazol-4-yl-heterocyclyl-carboxamide et procédés d'utilisation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |